Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy
Bryan A Faller, Barbara BurtnessDepartment of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USAAbstract: Pancreatic adenocarcinoma is a common malignancy that remains refractory to available therapies. Gemcitabine has long been the standard, first-line agent in advanced disease. The e...
Enregistré dans:
Auteurs principaux: | Bryan A Faller, Barbara Burtness |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2009
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/90b8799b8dd04c1cb305dd9a708ac4e9 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Epidermal Growth Factor Receptor and Its Role in Pancreatic Cancer Treatment Mediated by Nanoparticles
par: Grapa CM, et autres
Publié: (2019) -
Aptamer-Conjugated Gold Nanoparticles Targeting Epidermal Growth Factor Receptor Variant III for the Treatment of Glioblastoma
par: Peng L, et autres
Publié: (2020) -
A novel small peptide as an epidermal growth factor receptor targeting ligand for nanodelivery in vitro
par: Han CY, et autres
Publié: (2013) -
Targeted delivery of polyamidoamine-paclitaxel conjugate functionalized with anti-human epidermal growth factor receptor 2 trastuzumab
par: Ma P, et autres
Publié: (2015) -
Polymeric nanoparticles conjugate a novel heptapeptide as an epidermal growth factor receptor-active targeting ligand for doxorubicin
par: Liu CW, et autres
Publié: (2012)